RXRX Stock Pops as Buzz Builds Around NVIDIA Backing and Dubai Expansion
Investors eye potential short squeeze as Recursion gains traction at GITEX Global
RXRX is lighting up trading discussions this week, climbing sharply as market chatter around its high short interest and potential catalysts intensifies. Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), which operates in the biotechnology sector, closed the regular session at $6.68, up nearly 14%, and extended gains in after-hours trading, moving higher to $6.83.
The surge comes as the company presented at the GITEX Global conference in Dubai, a high-profile technology gathering where innovative health tech and AI-driven biotech solutions are taking center stage. What has caught many traders’ attention is the combination of rising volume, strong community sentiment, and a bullish narrative fueled by heavyweight backing from NVIDIA Corporation (NASDAQ: NVDA).
The buzz on Stocktwits has pushed RXRX into the platform’s top trending tickers, hitting the #4 spot among equities. Traders are openly discussing the possibility of a short squeeze, given the stock’s elevated short interest and growing retail enthusiasm. Many market participants see NVIDIA’s investment in Recursion as a strategic bet on the integration of artificial intelligence and drug discovery, a field with massive growth potential.
NVIDIA’s stake in Recursion continues to be perceived as a strong vote of confidence in the biotech’s AI-driven platform. As the AI trade remains one of the hottest narratives on Wall Street, any company connected to a major name like NVIDIA tends to attract investor attention fast. The ongoing rally also aligns with increased activity in AI-related healthcare stocks, which have outperformed broader markets in recent months.
Another key factor driving momentum is Recursion’s potential expansion in the Middle East. According to chatter emerging from the conference, the company may explore new partnerships or collaborations in the region. This is being interpreted as a growth driver, especially as sovereign wealth funds and tech accelerators continue to invest heavily in AI and health innovation. Traders view any hint of geographic expansion as a signal that Recursion could be positioning itself to capture new markets and diversify its revenue streams.
The timing of this rally is also intriguing. October has historically been a volatile but opportunistic month for small and mid-cap stocks, especially those with significant short interest. RXRX fits that profile perfectly. According to recent market data, Recursion has a short interest ratio that remains elevated, making it a prime candidate for aggressive speculative moves if buying pressure continues.
Social sentiment plays a major role here too. Conversations on platforms like Stocktwits and X (formerly Twitter) show a noticeable shift in tone from cautious optimism to outright bullishness. Some traders are even comparing the setup to previous short squeeze plays in the biotech space, though it’s important to remember that past patterns never guarantee future performance.
Institutional and retail traders alike are now watching closely for upcoming catalysts. With its visibility boosted, any partnership announcements, data releases, or product developments could fuel the next leg up. For now, RXRX remains one of the most talked-about tickers on the market, riding a wave of momentum, speculation, and strategic backing from one of the most powerful companies in the AI world.
Whether this run turns into a sustained breakout or a short-term squeeze remains to be seen. But one thing is clear: Recursion has captured the market’s attention, and NASDAQ: RXRX has firmly earned its place on this week’s watchlist of momentum traders.